Comprehensive review confirms that the Oncotype DX Breast Recurrence Score ® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity ...

MADISON, Wis., April 28, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that recommended use of its Oncotype DX Breast Recurrence ...

Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced the presentation of new data further reinforcing the utility of its Oncotype DX Breast Recurrence Score(R) ...

Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the expanded use of ...

First clinical validation of the Oncodetect ® test to be presented in triple negative breast cancer; signals highly sensitive molecular residual disease (MRD) detection The Oncotype DX® test is ...

Pertuzumab/Docetaxel/Carboplatin/Trastuzumab Regimen in Human Epidermal Growth Factor Receptor 2–Positive Early, Locally Advanced, and Oligometastatic Breast Cancer ...

In 2011, when Manjiri Bakre started her company, OncoStem, she was keen on developing a cost-effective, accurate, and ...

* Genomic Health - results from 15 Oncotype DX studies showing Oncotype Dx breast cancer test's ability to change treatment decisions in breast cancer patients Source text for Eikon: Further company ...

Continuous financial toxicity screening in community oncology. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.

May 5, 2011 — Several genomic tests for use in breast cancer are now available, but how they compare and relate to one another remains a "clinical challenge for practicing physicians," according to a ...

Initial results were announced today from the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, a multi-center prospectively conducted trial of more than 10,000 women with early ...